Compare SLRC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLRC | REPL |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 818.3M | 781.3M |
| IPO Year | 2007 | 2018 |
| Metric | SLRC | REPL |
|---|---|---|
| Price | $14.95 | $7.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $16.04 | $11.13 |
| AVG Volume (30 Days) | 234.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 10.96% | N/A |
| EPS Growth | ★ 25.71 | 5.25 |
| EPS | ★ 1.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.64 | $2.68 |
| 52 Week High | $17.94 | $14.80 |
| Indicator | SLRC | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 53.17 |
| Support Level | $14.76 | $7.43 |
| Resistance Level | $15.21 | $8.41 |
| Average True Range (ATR) | 0.30 | 0.53 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 48.13 | 77.61 |
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.